Stock Analysis

Polycab India Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

NSEI:POLYCAB
Source: Shutterstock

Polycab India Limited (NSE:POLYCAB) investors will be delighted, with the company turning in some strong numbers with its latest results. The company beat expectations with revenues of ₹180b arriving 3.4% ahead of forecasts. Statutory earnings per share (EPS) were ₹118, 5.1% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

View our latest analysis for Polycab India

earnings-and-revenue-growth
NSEI:POLYCAB Earnings and Revenue Growth May 13th 2024

Following the latest results, Polycab India's 25 analysts are now forecasting revenues of ₹213.0b in 2025. This would be a meaningful 18% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to ascend 17% to ₹139. In the lead-up to this report, the analysts had been modelling revenues of ₹201.7b and earnings per share (EPS) of ₹130 in 2025. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.

With these upgrades, we're not surprised to see that the analysts have lifted their price target 9.1% to ₹5,888per share. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Polycab India, with the most bullish analyst valuing it at ₹7,708 and the most bearish at ₹3,925 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of Polycab India'shistorical trends, as the 18% annualised revenue growth to the end of 2025 is roughly in line with the 18% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 19% annually. It's clear that while Polycab India's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Polycab India's earnings potential next year. There was also an upgrade to revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Polycab India analysts - going out to 2027, and you can see them free on our platform here.

You still need to take note of risks, for example - Polycab India has 2 warning signs (and 1 which is concerning) we think you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Polycab India is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.